Pfizer is the most recent addition to the Leadership level. Representatives with the company say the Foundation has demonstrated its commitment to ensuring that funds are invested in quality training and research projects.
You Might Also Like
Explore This IssueSeptember 2014
Also By This Author
“Pfizer is honored to be involved in the Rheumatology Research Foundation, which is providing opportunities and access to important resources for future leaders in rheumatology,” says Andrew Koenig, DO, FACR, Inflammation and Immunology group leader, North America Medical Affairs, Pfizer Inc. “We are pleased to have the opportunity to engage at the Leadership level and join others in our industry in the Corporate Roundtable in order to make a significant impact on the future of innovation in rheumatoid arthritis and similar autoinflammatory diseases.”
Because of generous gifts from CRT partners, as well as members of the rheumatology community, and patients and their loved ones, the Foundation will continue to provide essential support for the brightest minds in the field. In fiscal year 2015 (July 1, 2014–June 30, 2015), the Foundation will be providing awards and grants to 110 students, residents, fellows, researchers and others, representing a commitment of more than $13 million in funding support. Nearly $6 million will be invested in educating, training and developing the careers of rheumatology professionals. The remainder will fund essential research into rheumatoid arthritis and similar autoinflammatory diseases.